Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Liquidity Ratios (Summary)

Biogen Inc., liquidity ratios (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Current ratio
Quick ratio
Cash ratio

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).


Current Ratio
The current ratio exhibits some fluctuations over the observed periods, ranging roughly between 1.7 and 3.23. It started at 2.29 in early 2017, reaching a notable peak of 3.23 in the first quarter of 2018, indicating increased liquidity during that time. However, after this peak, there was a gradual decrease, with values generally oscillating around the 2.0 mark. By late 2021 and into 2022, the ratio mostly remained near or slightly above 2.0, with a final rise to 2.49 in the third quarter of 2022. Overall, the current ratio suggests a generally healthy but somewhat volatile liquidity position across the quarters.
Quick Ratio
The quick ratio follows a pattern similar to that of the current ratio, but consistently at lower values, as expected since it excludes inventory. Starting at 1.57 in March 2017, it peaked at 2.67 in the first quarter of 2018. Subsequently, the ratio experienced declines and fluctuations, often falling below 1.5 in the periods from late 2019 through 2021, indicating a more conservative liquidity status excluding inventory. Towards the end of the data range, there is a recovery trend, with the ratio improving to 1.76 by September 2022. The quick ratio's trend reflects moderate short-term liquidity strength with periods of tightening.
Cash Ratio
The cash ratio shows greater variability with values between approximately 0.7 and 1.88. It began near one in early 2017, rising significantly to 1.88 by the first quarter of 2018, signifying strong cash and cash equivalents relative to current liabilities during that period. Afterward, the ratio shows a downward trend reaching lows around 0.7 in late 2020 and late 2021, indicating reduced cash liquidity relative to current liabilities at these times. However, a recovery phase is noticeable towards the end of the series, climbing back to 1.25 in the third quarter of 2022. This ratio implies occasional tightening in immediate cash availability followed by periodic improvement.
Overall Liquidity Insights
The liquidity ratios collectively reveal that the company maintained overall adequate short-term financial health but experienced periods of tightening, especially between late 2018 and 2021. Peaks around early 2018 indicate a strong liquidity position, which subsided somewhat in subsequent years. The partial recovery across all ratios towards 2022 suggests a strategic effort to improve liquidity. The fluctuations, particularly in the cash ratio, highlight changes in the composition of liquid assets, with cash and equivalents occasionally becoming relatively constrained compared to broader current assets.

Current Ratio

Biogen Inc., current ratio calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


Current Assets
The current assets showed an overall increasing trend from March 2017 through September 2022, starting at approximately $6.86 billion and rising to nearly $9.77 billion. However, the pattern is marked by fluctuations, with notable peaks and troughs. For example, there was a significant increase in the first quarter of 2018 reaching nearly $10.2 billion, followed by a decline through the rest of 2018 and 2020, and then recovering again towards the latter periods in 2022. The fluctuations suggest variable working capital requirements or changes in asset liquidity across quarters.
Current Liabilities
Current liabilities demonstrated a less consistent pattern, starting at about $2.99 billion in March 2017 and ending near $3.93 billion in September 2022. The values fluctuated considerably without a clear linear trend. Spikes occurred at the end of 2019 and into mid-2022, where liabilities escalated to over $5 billion, indicating periods of higher short-term obligations. These peaks may reflect temporary increases in payable obligations or accrued expenses.
Current Ratio
The current ratio experienced significant variation during the period under review. It began at 2.29 in March 2017 and reached a high of 3.23 in March 2018, indicating a strong liquidity position at that point. Following this peak, the ratio generally declined, hitting lows around 1.7 during late 2021 and early 2022, signifying more constrained liquidity. The ratio rose again towards the end of the dataset to 2.49 in September 2022, suggesting a recovery in short-term financial health. The volatility in the current ratio reflects the combined effects of the fluctuations in current assets and liabilities, with periods of both strong and weakened liquidity positions over the quarters.

Quick Ratio

Biogen Inc., quick ratio calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Cash and cash equivalents
Marketable securities
Accounts receivable, net
Due from anti-CD20 therapeutic programs
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


Total quick assets
The total quick assets display notable fluctuations over the periods analyzed. Beginning at approximately $4.7 billion in March 2017, the value generally increased, reaching a peak of about $8.4 billion in March 2018, before decreasing sharply in June 2018 to around $5.7 billion. Subsequently, the quick assets showed variability, with minor peaks and troughs, declining towards the end of 2020 to approximately $4.9 billion. Starting in 2021, total quick assets mostly stabilized, fluctuating in the $4.7 billion to $5.7 billion range, with a significant increase in the third and fourth quarters of 2022, rising to nearly $6.9 billion. This pattern suggests periods of asset accumulation followed by reductions and eventual stabilization with a recent upward movement.
Current liabilities
Current liabilities experienced moderate variation throughout the timeframe. Beginning at roughly $3.0 billion in March 2017, liabilities fluctuated slightly, remaining near the $3.1 billion to $3.4 billion range until the third quarter of 2019. At this point, a sharp increase occurred, with liabilities rising to over $4.4 billion and continuing to increase toward the end of 2019. Subsequently, the liabilities dropped to about $3.4 billion by mid-2020 but rose again towards the end of the study period, reaching over $5.0 billion in the middle of 2022 before settling around $3.9 billion in the third quarter of 2022. These developments indicate episodic growth in obligations, with some volatility in the medium term.
Quick ratio
The quick ratio presents a dynamic profile throughout the observed intervals. Initially, it was relatively stable around 1.5 to 1.8, then it surged to a high of 2.67 in March 2018, reflecting a strong liquidity position at that time. However, this ratio declined considerably after that peak, hitting lows near 1.39 in the first half of 2020. Following this decline, there were improvements during the latter part of 2020 and early 2021, though subsequent quarters showed a general downward trend, dipping to approximately 1.21 by the fourth quarter of 2021. Towards the middle and latter portions of 2022, the liquidity ratio showed recovery, increasing back to about 1.76. Overall, the quick ratio indicates periods of strong liquidity interspersed with declines, suggesting fluctuating ability to cover short-term liabilities with liquid assets.
Summary
The financial data reveal a trend of fluctuating liquid assets and liabilities, with significant peaks and troughs influenced by external or operational factors not directly specified. The substantial increase in total quick assets in early 2018 followed by its sharp decrease implies potential asset reallocation or receipt of large cash inflows and outflows. Concurrent fluctuations in current liabilities suggest varying short-term debt levels or payment cycles affecting the company’s obligations. The quick ratio trending higher in early 2018 followed by a decline and eventual partial recovery indicates shifts in liquidity management efficiency over time. The most recent data show an improvement in liquidity alongside increasing quick assets and somewhat reduced liabilities, which may reflect strengthened short-term financial stability by the end of the period analyzed.

Cash Ratio

Biogen Inc., cash ratio calculation (quarterly data)

Microsoft Excel
Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Selected Financial Data (US$ in thousands)
Cash and cash equivalents
Marketable securities
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

1 Q3 2022 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The analysis of the quarterly financial data reveals several notable trends in the company’s liquidity and short-term financial position over the reported periods.

Total Cash Assets
The total cash assets exhibit significant fluctuations throughout the timeframe. Initially, the cash assets gradually increased from approximately $2.88 billion at the end of Q1 2017 to a peak of about $5.92 billion in Q1 2018. After this spike, there was a marked decline to roughly $2.61 billion by Q4 2020. From 2021 onward, cash holdings exhibited a recovery trend, reaching nearly $4.91 billion by Q3 2022.
Current Liabilities
Current liabilities show a less volatile but overall increasing pattern. The values hovered around $3.0 to $3.5 billion during 2017 and 2018, before experiencing a rise to a range above $4.0 billion starting in Q4 2019. The highest current liabilities were recorded at about $5.02 billion in Q2 2022, indicating a growing short-term debt or payables position over time, especially from 2019 onwards.
Cash Ratio
The cash ratio, representing the ability to cover current liabilities with cash assets alone, varied between 0.7 and 1.88 during the periods reviewed. The ratio peaked at 1.88 in Q1 2018, reflecting a strong liquidity position at that time. Subsequent quarters saw a general downward trend in the cash ratio, occasionally dipping below 1.0 which indicates that cash alone was insufficient to cover all current liabilities at those points. Notably, the cash ratio was particularly low around Q4 2020 and Q4 2021, at 0.7, suggesting tighter liquidity during those quarters. Towards Q3 2022, the cash ratio improved to approximately 1.25, indicating a strengthening liquidity position.

Overall, the data indicates that the company experienced considerable volatility in its cash assets, with a peak in early 2018 followed by a notable decrease and subsequent partial recovery. Meanwhile, current liabilities have generally increased, particularly after 2018, leading to fluctuating cash ratios that reflect varying liquidity conditions. Periods of cash ratio below 1.0 suggest potential liquidity constraints, whereas higher ratios signify periods of financial strength and comfortable coverage of short-term obligations by cash. These trends underscore the importance of continued cash management efforts to ensure liquidity resilience given the observed fluctuations in liabilities and cash positions.